


JC474 U.S. PTO  
12/20/00

Please type a plus sign (+) inside this box ☐

Attorney Docket P1729C1

PATENT

CERTIFICATION UNDER 37 CFR 1.10	
EM 168886705 US: Express Mail Number	December 20, 2000: Date of Deposit
I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.	
 Richard B. Love	

JC474 U.S. PTO  
09/811384  
12/20/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION  
Assistant Commissioner of Patents  
Washington, D.C. 20231

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

**Martin M. Bednar  
Cordell E. Gross  
G. Roger Thomas**

Title: **Anti-CD18 Antibodies in Stroke**

**1. Type of Application**

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. \_\_, filed \_\_, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☒ continuation ☐ divisional application claiming priority to application Serial Number 09/251,652, filed 17 February 1999, which is a continuation-in-part application claiming priority to non-provisional application 08/788,800 filed 22 January 1997, which claims priority to provisional application 60/093,038 filed 23 January 1996 (which was converted from non-provisional application U.S. Ser. No. 08/589,982), the entire disclosures of which are hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)  
(Non-provisional )**

40 pages of specification  
2 pages of claims  
1 page(s) of abstract

1 page(s) of abstract  
5 sheet(s) of drawings  
☐ formal ☒ informal

### 3. Declaration or Oath

*(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)*  
X An unsigned execution declaration of the inventor is enclosed. An executed declaration of the inventors will follow.

*(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*  
— A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

*(for Cont./Div. where inventor(s) being deleted)*  
— A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

### 4. Assignment

*(for new and CIP applications)*  
— An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with attached Recordation Form Cover Sheet ☐ will follow.

*(for cont./div.)*  
X The prior application is assigned of record to Genentech, Inc.

### 5. Amendments (for continuation and divisional applications)

— Cancel in this application original claims \_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

X A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

#### Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

— Amend the specification by inserting before the first line the sentence:

--This is a

— non-provisional application  
— continuation  
— divisional  
— continuation-in-part

of co-pending application(s)

- \_\_\_\_\_ Serial\_ filed on, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --
- \_\_\_\_\_ International Application \_ filed on \_\_ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--
- \_\_\_\_\_ provisional application No. \_ filed \_\_, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--

#### 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$710.00
Total Claims	18	- 20 =	0	X \$18.00	\$0.00
Independent Claims	1	- 3 =	0	X \$80.00	\$0.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
Filing Fee Calculation					\$710.00

#### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$710.00 **A duplicate copy of this transmittal is enclosed.**

#### 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

#### 9. Additional Papers Enclosed

- ☒ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☒ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other: Petition to Extend Time (five months)

#### 10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

X   A petition, fee and/or response is filed herewith to extend the term  
in the pending prior application until December 20, 2000.

       A copy of the petition for extension of time in the **prior** application  
is attached.

X Address all future communications to:

Respectfully submitted,  
GENENTECH, INC.

By: Richard B. Love  
Richard B. Love  
Reg. No. 34,659  
Telephone No. (650) 225-5530




09157

PATENT TRADEMARK OFFICE

Figure 1 is a schematic representation of the 12 genes and their organization. The genes are labeled on the left side of the diagram: D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, and D12. Each gene is represented by a horizontal bar with internal lines indicating exons and introns. The genes are arranged in a vertical column, with D1 at the top and D12 at the bottom. The diagram shows the relative positions of the genes and their internal structure.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Rule 53(b) Continuation of Application U.S. Serial No.: 09/251,652  Filed: 17 FEBRUARY 1999  For: CO-ADMINISTRATION OF A THROMBOLYTIC AND AN ANTI- CD18 ANTIBODY</p>	<p>Group Art Unit: Not Yet Assigned  Examiner: Not assigned  EM 168886705 US: Express Mail Number December 20, 2000: Date of Deposit  I hereby certify that this correspondence, consisting of Formal Documents for P1729C1, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.  December 20, 2000   Richard B. Love</p>
---	---

CERTIFICATE RE: SEQUENCE LISTING


Box Application  
Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,  
GENENTECH, INC.

Date: December 20, 2000

By:   
Richard B. Love  
Reg. No. 34,659  
Telephone No. (650) 225-5530



09157

PATENT TRADEMARK OFFICE